INT63222

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 1996
Last Reported 2009
Negated 0
Speculated 0
Reported most in Abstract
Documents 8
Total Number 8
Disease Relevance 4.33
Pain Relevance 0.37

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (MGAM) plasma membrane (MGAM) carbohydrate metabolic process (MGAM)
Anatomy Link Frequency
internal 1
small intestine 1
intestine 1
MGAM (Homo sapiens)
Pain Link Frequency Relevance Heat
Pain 9 99.70 Very High Very High Very High
Gabapentin 1 99.04 Very High Very High Very High
Angina 4 82.00 Quite High
Serotonin 2 57.96 Quite High
Bile 1 56.84 Quite High
Inflammation 6 54.56 Quite High
imagery 2 43.12 Quite Low
agonist 5 25.00 Low Low
Dopamine 4 25.00 Low Low
Bioavailability 1 25.00 Low Low
Disease Link Frequency Relevance Heat
Diabetes Mellitus 139 99.80 Very High Very High Very High
Muscle Disease 1 99.78 Very High Very High Very High
Glycogen Storage Disease 1 98.94 Very High Very High Very High
Dumping Syndrome 8 98.84 Very High Very High Very High
Disease 27 97.92 Very High Very High Very High
Ulcers 2 94.96 High High
Syndrome 5 93.72 High High
Phobia 2 92.88 High High
Hepatic Encephalopathy 108 92.56 High High
Hypoglycemia 18 91.16 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
A rapid, sensitive and accurate liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated for the quantification of miglitol (CAS 72432-03-2), an alpha-glucosidase inhibitor, in human plasma using gabapentin (CAS 60142-96-3) as internal standard (IS).
Negative_regulation (inhibitor) of alpha-glucosidase in internal associated with gabapentin
1) Confidence 0.43 Published 2006 Journal Arzneimittelforschung Section Abstract Doc Link 16821643 Disease Relevance 0 Pain Relevance 0.10
Acarbose, alpha-glucosidase inhibitor, suppresses the breakdown of carbohydrates in the small intestine and consequently reduced osmolarity.
Negative_regulation (inhibitor) of alpha-glucosidase in small intestine
2) Confidence 0.43 Published 1996 Journal Masui Section Abstract Doc Link 8721135 Disease Relevance 0.52 Pain Relevance 0
[The effect of alpha-glucosidase inhibitor on burning epigastralgia in dumping syndrome: a case report].
Negative_regulation (inhibitor) of alpha-glucosidase associated with pain and dumping syndrome
3) Confidence 0.43 Published 1996 Journal Masui Section Title Doc Link 8721135 Disease Relevance 0.53 Pain Relevance 0.10
Late-onset Pompe's disease (acid maltase deficiency, glycogen storage disease type II) is a slowly progressive myopathy caused by deficiency of acid alpha-glucosidase.
Negative_regulation (deficiency) of alpha-glucosidase associated with muscle disease, glycogen storage disease and disease
4) Confidence 0.20 Published 2005 Journal Brain Section Abstract Doc Link 15659425 Disease Relevance 0.46 Pain Relevance 0
Alpha-glucosidase inhibitors
Negative_regulation (inhibitors) of Alpha-glucosidase
5) Confidence 0.11 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2515417 Disease Relevance 0.53 Pain Relevance 0
NB-DNJ, a compound originally developed as an alpha-glucosidase inhibitor and structurally unrelated to PDMP, is an N-alkylated imino sugar and is an inhibitor of GlcCer synthase.
Negative_regulation (inhibitor) of alpha-glucosidase
6) Confidence 0.05 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504062 Disease Relevance 0.33 Pain Relevance 0
It inhibits alpha-glucosidase activity in the intestine and delays digestion of ingested carbohydrates.
Negative_regulation (inhibits) of alpha-glucosidase in intestine
7) Confidence 0.03 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2724191 Disease Relevance 1.05 Pain Relevance 0.08
This study will extend the current data on Cycloset™ safety, tolerability and efficacy in individuals with type 2 diabetes to include its effects in combination with thiazolodinediones, insulin secretagogues, metformin, alpha-glucosidase inhibitors and exogenous insulin regimens.


Negative_regulation (inhibitors) of alpha-glucosidase associated with diabetes mellitus
8) Confidence 0.01 Published 2007 Journal BMC Endocr Disord Section Abstract Doc Link PMC1924849 Disease Relevance 0.90 Pain Relevance 0.08

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox